Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors
作者:Matthew G. LaPorte、Zhuzhu Wang、Raffaele Colombo、Atefeh Garzan、Vsevolod A. Peshkov、Mary Liang、Paul A. Johnston、Mark E. Schurdak、Malabika Sen、Daniel P. Camarco、Yun Hua、Netanya I. Pollock、John S. Lazo、Jennifer R. Grandis、Peter Wipf、Donna M. Huryn
DOI:10.1016/j.bmcl.2016.06.017
日期:2016.8
studies of a 1,2,4-triazolo-[3,4-b]thiadiazine scaffold, identified in an HTS campaign for selective STAT3 pathway inhibitors, determined that a pyrazole group and specific aryl substitution on the thiadiazine were necessary for activity. Improvements in potency and metabolic stability were accomplished by the introduction of an α-methyl group on the thiadiazine. Optimized compounds exhibited anti-proliferative
在1,2-,3,4-三唑并[3,4- b ]噻二嗪支架上的结构-活性关系研究在针对选择性STAT3途径抑制剂的HTS运动中确定,确定吡唑基和噻二嗪上的特定芳基取代是必要的活动。通过在噻二嗪上引入α-甲基来实现效力和代谢稳定性的改善。优化的化合物表现出抗增殖活性,磷酸化的STAT3水平降低以及对STAT3目标基因的影响。这些化合物代表了针对STAT3途径的进一步药物发现努力的起点。